Table 2. Pre-clinical and clinical trials evaluating anti–CD73 therapeutic strategies.

Study	Phase/Condition	Experimental arm (s)	Efficiency	Reference
MedImmune/2016	Phase 1(NCT02503774) Advanced Solid Tumors	Arm A: MEDI9447 Arm B: MEDI9447+MEDI4736	Recruiting	www.clinicaltrials.gov
Hay/2015	Mice model CT26 colon cancer	Arm A: Untreated Arm B: Isotype Mix Arm C: MEDI9447 Arm D: Anti-PD1 Arm E: MEDI9447+Anti-PD1	Enhances anti-tumor activity of anti-PD1	[31]
Stagg/2010	Mice model 4T1.2 breast cancer	Arm A: Ig Arm B: anti-CD73 mAb (TY/23)	Inhibits breast tumor growth and metastasis	[30]
Terp/2013	Mice model LM3 hepatocellular cancer	Arm A: anti-CD73 AD2 mAb Arm B: control mAb	Inhibits the ability of circulating tumor cells to extravasate and colonize, leading to inhibition of metastasis	[32]
Allard/2013	Mice model MC38-OVA colon cancer, RM-1 prostate cancer, 4T1.2 breast cancer	Arm A: Ig Arm B: anti-CD73 mAb (TY/23) Arm C: anti-PD-1 mAb (RMP1-14) Arm D: anti-CTLA-4 mAb (UC10-4F10) Arm E: TY/23+RMP1-14 Arm F: TY/23+ UC10-4F10	Enhances the therapeutic activity of anti-PD-1 and anti-CTLA-4 mAbs	[33]
Wang/2011	Mice model ID8 ovarian cancer	Arm A: Untreated Arm B: APCP Arm C: T cells Arm D: T cells+APCP* Arm E: anti-CD73 mAb (TY/23) Arm F: T cells+TY/23	Inhibits tumor growth and augments the efficacy of adoptive T cell therapy	[11]

* APCP: selective inhibitor α,β-methylene adenosine 5′-diphosphate.